01st April 2022 | Pharma Updates
Bayer plans to open 27 telemedicine centres throughout India
Over the next two years, Bayer wants to open 27 Telemedicine centres in 12 aspirational districts throughout eight states. Each centre is anticipated to 35,000 to 50,000 people served.
Mankind Pharma begun preparations for an Initial Public Offering
Mankind Pharma, which produces top selling condom brands Manforce Condoms, Kaloree 1 and Prega News and is funded by ChrysCapital to seek a massive IPO in 2022.
Fresenius has agreed to two acquisitions to strengthen its Kabi drugs division
Fresenius’s division Kabi has decided to purchase a controlling stake in Insud Pharma’s mAbxience subsidiary in order to develop its business producing lower-cost versions drugs.
For its new 'long haul' psoriasis campaign, Sun has turned to travel
Sun Pharma is sure that clinical data helped its four-times-a-year psoriasis treatment Ilumya stand out among the crowd at the American Academy of Dermatology Annual Meeting.
Total number of cases handled by Covid has surpassed 488.3 million
The global coronavirus caseload has surpassed 488.3 million, with more than 6.14 million deaths and more than 10.88 billion vaccines.
Triumeq PD has been approved by the FDA for use in HIV-positive children
FDA has accepted NDA for Trimeq PD, a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir, and lamivudine treatment for children with HIV.
FDA approval of Opdualag for bone health following cancer therapy
FDA has approved relatlimab plus nivolumab for the treatment of unresectable or metastatic melanoma in patients aged 12 and older.
Pacritinib in Myelofibrosis: FDA Approval Insights
Pacritinib was given fast approval by the FDA for the treatment of adults with intermediate or high-risk primary or secondary cancers (post-essential thrombocythemia) myelofibrosis.
Clovis Oncology seek FDA approval for ovarian cancer drug
Rubraca, when taken as a maintenance medication for women with ovarian cancer, increased survival. The findings come from a 538-woman Phase 3 clinical trial that was double-blind and placebo-controlled.
FDA approved the first LAG-3 inhibitor; significant step forward in immunooncology
With the FDA’s approval of Bristol Myers Squibb’s Opdualag, for the treatment of metastatic melanoma, a new class of immune checkpoint inhibitors has entered the market.
